Executive Vice President, Head of Research & Investments
Jim runs the group at Royalty Pharma that is tasked with sourcing and analyzing new investments; in ten years, RP has invested close to $12 billion in innovative biopharma products and partnerships. He joined Royalty Pharma in July 2008 after a decade on Wall Street as a biotechnology analyst. Prior to joining Royalty Pharma, Jim was Managing Director and Head of Healthcare Equity Research at Friedman Billings Ramsey. He was previously a biotech analyst at Bank of America and CIBC World Markets Corp (now Oppenheimer & Co). He holds a BA from Furman University and a PhD in biochemistry and molecular genetics from the University of Alabama at Birmingham. He was a postdoctoral fellow at the Yale University School of Medicine, where he also worked in technology transfer. He is a director of Avillion and is on Memorial Sloan Kettering's advisory committee for its technology development fund.